Trial Outcomes & Findings for Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder (NCT NCT03526354)

NCT ID: NCT03526354

Last Updated: 2025-05-23

Results Overview

The Timeline Follow Back (TLFB) scale is used to measure weekly substance use for alcohol, marijuana, cocaine, and/or heroin by assessing the number of days a person used substances in the past week, on a scale from 0 to 7 \[0 = no substances that week; 7 = substance use every day\]. The outcome measure was the number of days per week that participants used a substance. If participants use more than one substance, only the primary substance (one used mostly frequently) was analyzed. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

50 participants

Primary outcome timeframe

12 weeks

Results posted on

2025-05-23

Participant Flow

Participant milestones

Participant milestones
Measure
Experimental
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Overall Study
STARTED
21
18
Overall Study
COMPLETED
15
14
Overall Study
NOT COMPLETED
6
4

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Total
n=39 Participants
Total of all reporting groups
Age, Continuous
36.1 years
STANDARD_DEVIATION 12.0 • n=99 Participants
39.8 years
STANDARD_DEVIATION 11.2 • n=107 Participants
37.8 years
STANDARD_DEVIATION 11.6 • n=206 Participants
Sex: Female, Male
Female
5 Participants
n=99 Participants
4 Participants
n=107 Participants
9 Participants
n=206 Participants
Sex: Female, Male
Male
16 Participants
n=99 Participants
14 Participants
n=107 Participants
30 Participants
n=206 Participants
Race/Ethnicity, Customized
Caucasian
8 Participants
n=99 Participants
9 Participants
n=107 Participants
17 Participants
n=206 Participants
Race/Ethnicity, Customized
African American
9 Participants
n=99 Participants
10 Participants
n=107 Participants
19 Participants
n=206 Participants
Race/Ethnicity, Customized
Other
4 Participants
n=99 Participants
0 Participants
n=107 Participants
4 Participants
n=206 Participants
Region of Enrollment
United States
21 participants
n=99 Participants
18 participants
n=107 Participants
39 participants
n=206 Participants

PRIMARY outcome

Timeframe: 12 weeks

The Timeline Follow Back (TLFB) scale is used to measure weekly substance use for alcohol, marijuana, cocaine, and/or heroin by assessing the number of days a person used substances in the past week, on a scale from 0 to 7 \[0 = no substances that week; 7 = substance use every day\]. The outcome measure was the number of days per week that participants used a substance. If participants use more than one substance, only the primary substance (one used mostly frequently) was analyzed. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome. While the TLFB was assessed weekly, the outcome measure reported is the change in substance use between Week 0 (Baseline) and Week 12 (End of Study). A decrease in number of days/week that substances were used indicates an improved (better) outcome.

Outcome measures

Outcome measures
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Timeline Follow Back (TLFB)
-1.765 score on a scale
Interval -3.117 to -0.413
-.532 score on a scale
Interval -1.91 to 0.846

PRIMARY outcome

Timeframe: 12 weeks

The Visual Analog Scale (VAS) measures substance craving. Subjects will make a mark on an unlabeled 100-millimeter line indicating their desire to use a particular substance over the past 7-days. A score of 0 indicates no desire to use and 100 indicating the strongest desire to use possible. The assessment was done weekly. Subjects reported craving for any substances they used that week with a separate mark for each substance (e.g., a mark for alcohol craving and another mark for marijuana). For outcome measures, only the primary substance (the substance used most frequently, as determined by the Timeline Follow Back assessment) was included. While cravings were assessed weekly, only the change in craving from Week 0 (Baseline) to Week 12 (End of Study) is reported; a decreased score (reduction in cravings) represents an improved outcome.

Outcome measures

Outcome measures
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Visual Analog Scale (VAS)
-33.421 score on a scale
Interval -49.305 to -17.536
-8.898 score on a scale
Interval -25.511 to 7.716

SECONDARY outcome

Timeframe: 12 weeks

The amount of money spent on substances over a 7-day period will also be recorded as part of each weekly visit. Decreased money spent on substances over a 7-day period will also be considered an improved outcome.

Outcome measures

Outcome measures
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Amount of Money Spent on Substances
-20.974 dollars spent
Interval -51.647 to 9.7
14.605 dollars spent
Interval -16.497 to 45.707

SECONDARY outcome

Timeframe: 12 Weeks

The Positive and Negative Symptom Scale (PANSS) is a measure used to assess symptom severity in patients with schizophrenia. Each item (symptom) is scored on a 7-point scale (1 = absent and 7 = extreme). The minimum and maximum values for the total 30 items (PANSS Total Score) are 30 and 210 respectively. Higher scores represent higher levels of psychiatric symptoms (worse outcomes). The PANSS has three subscales: "Positive" (measuring positive symptoms), "Negative" (measuring negative symptoms), and "General Psychopathology" (measuring general psychiatric symptoms). There are 7 items each for Positive and Negative subscales (minimum value for each is 7, and maximum value is 49), and 16 items for General Psychopathology (minimum value is 16 and maximum is 112). This study looked at changes in all 3 subscales and the PANSS total score between Week 0 (Baseline) and Week 12 (End of Study), with a decrease in score indicating improved psychiatric functioning.

Outcome measures

Outcome measures
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Positive and Negative Symptom Scale (PANSS)
-3.690 score on a scale
Interval -9.188 to 1.807
-.274 score on a scale
Interval -5.996 to 5.447

SECONDARY outcome

Timeframe: 12 Weeks

The Clinical Global Impression - Severity (CGI-S) measures illness severity on a 7-point Likert scale, with a higher score indicating higher illness severity and worse outcomes (1 = "Normal, not at all ill" and 7 = "Among the most extremely ill patients"). The outcome measure for this study looked at the change in the CGI-S score between Week 0 (Baseline) and Week 12 (end of study), with a reduction in score indicating improved outcomes.

Outcome measures

Outcome measures
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Clinical Global Impression - Severity
-.320 score on a scale
Interval -0.601 to -0.038
-.128 score on a scale
Interval -0.413 to 0.156

SECONDARY outcome

Timeframe: 12 Weeks

The Heinrichs Carpenter Quality of Life Scale (QOL)is a 21-item scale providing information on symptoms and functioning in patients with schizophrenia. Items are scored on a 0-6 scale, with 0 being no evidence of that item (e.g., social relationships are virtually absent) and 6 being adequate evidence of that item (e.g., adequate social relationships). Two items (#1 - "Intimate relationship with household members" and # 12 - "Satisfaction with occupational role functioning") are scored a "9" if the item is not applicable (e.g., lives alone with no close family or does not have an occupational role). Therefore, total scores can range from 0 to 132 (if 9s are scored). A higher total score indicates better psychosocial functioning. For this study, the outcome measure looked at the change in total score between Week 0 and Week 12.

Outcome measures

Outcome measures
Measure
Experimental
n=21 Participants
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 Participants
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Heinrichs Carpenter Quality of Life Scale (QOL)
4.049 score on a scale
Interval -1.95 to 10.049
-5.146 score on a scale
Interval -11.293 to 1.001

Adverse Events

Experimental

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

Treatment as Usual

Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Experimental
n=21 participants at risk
Brexpiprazole 4mg daily for 12 weeks Brexpiprazole: Brexpiprazole 4mg daily for 12 weeks
Treatment as Usual
n=18 participants at risk
Stay on current antipsychotic medication for 12 weeks Treatment as Usual: Current antipsychotic medication for 12 weeks
Gastrointestinal disorders
Diarrhea
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
0.00%
0/18 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
General disorders
Fatigure/Tiredness
14.3%
3/21 • Number of events 3 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
0.00%
0/18 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
General disorders
Dizziness
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
5.6%
1/18 • Number of events 1 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
General disorders
Cold-like symptoms
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
16.7%
3/18 • Number of events 3 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
General disorders
Trouble Sleeping
9.5%
2/21 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
0.00%
0/18 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
General disorders
Nausea
14.3%
3/21 • Number of events 3 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
11.1%
2/18 • Number of events 2 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
General disorders
Restlessness/Irritability
4.8%
1/21 • Number of events 1 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.
5.6%
1/18 • Number of events 1 • Adverse event data were collected from each participant's screening through their study completion (Week 12 or Early Termination), an average of 3 months.

Additional Information

Dr. Xiaoduo Fan

UMass Chan Medical School

Phone: 5088566463

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place